“The global MicroRNA (miRNA) market is anticipated to surpass USD 980 Million by 2030”, says Visiongain

16 October 2019
Pharma

Visiongain has launched a new pharma report ‘’MicroRNA (miRNA) Market Report 2020-2030’’ by Product (Instruments, Isolation & purification, Quantification & detection, Functional analysis, Consumables), Services (MiRNA Profiling & Purification, MiRNA cDNA Synthesis, Sample collection, Detection, MiRNA functional studies), Application (Cancer, Cardiovascular Disease, Immunological Disorder, Infectious Diseases, Others), End Users (Academics and Research Institutes, Biotechnology, Pharmaceutical Companies, Other End Users), and Geography.

The global MicroRNA (miRNA) market is anticipated to grow at a lucrative CAGR of 18.3% and anticipated to surpass USD 980 Million by 2030.

MicroRNAs (miRNAs) are short non-coding RNAs binding to particular messenger RNAs (mRNAs) and regulating gene expression through either degradation or translational mRNA inhibition. MiRNAs play a key role in eukaryotic species growth as well as in many cellular and environmental procedures. While an organism has a limited variety of miRNAs compared to mRNAs, one miRNA can regulate several mRNA and affect the network of gene expression.

Recent improvements in MicroRNA applications such as prospective biomarkers in sophisticated diagnostics have accelerated the growth of new products and exponentially enhanced demand for miRNA. The use of bioinformatics and sophisticated technology (such as NGS) systems is set to drive market growth. The establishment of enormous amounts of government and private financing is one of the main variables contributing to market growth. Growth in this industry is driven by variables such as the benefits of miRNA sequencing over other techniques, increased launch of genomics products, and exponentially lower sequencing costs.

MicroRNAs' complex nature and their instability improve their developmental inconvenience. It is presumed that the issues connected with quantification and enhancement of MicroRNA study instruments such as microarrays hinder the market growth. Another significant constraint in emerging economies is the restricted life science infrastructure.

North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of owing to the presence of strong technical support and well-established research infrastructure in oncology, proteomics, genomics, and advanced diagnostics research. Also, approval of funds through the EU for initiatives such as EpimiRNA consortium is anticipated to boost growth in the European region.

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the rising adoption of advanced technologies and growing progress in genomic studies. Local players in Japan and China, such as TaKaRa Bio Inc., is involved in the development of products that includes kits and arrays, thus boosting the growth of the overall Asia Pacific region.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global miRNA market. Companies are also increasing their R&D, distribution, and management facilities to expand their business and hold a competitive edge in the market.

The comprehensive market report features companies such as Biodynamics Laboratory, Inc., BioGenex, Dharmacon, a Horizon Discovery Group Co., GeneCopoeia, Inc., Merck KGaA, Miltenyi Biotec, NanoString Technologies, Inc., New England Biolabs, OriGene Technologies, Inc., QIAGEN, Quantabio, SeqMatic LLC, Sistemic Scotland Limited, Synlogic, and Thermo Fisher Scientific, Inc. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020–2030 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

Read

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever